Catalyst Brief

← Calendar

ReadoutIn window

Merck Sharp & Dohme LLC — Pembrolizumab

Phase 3 primary completion: Pembrolizumab (MK-3475) with chemoradiotherapy in MIBC (KEYNOTE-992).

Date
Nov 2026
Type
Readout
Ticker
MRK
Indication
Muscle-invasive bladder cancer (MIBC)

Source ↗Add to calendar

Date history

Jan 1, 2027 → Nov 1, 2026Nov 17, 2026
Nov 1, 2026 → Jan 1, 2027Nov 17, 2026
Jan 1, 2027 → Nov 1, 2026Nov 17, 2026
Nov 1, 2026 → Jan 1, 2027Nov 17, 2026

Get told when this date moves

The weekly brief is free. Pro adds reminders 7 days and 1 day before.

More from Merck Sharp & Dohme LLC

  1. May2027
  2. May2027
  3. Jan2027
  4. Jan2027